Exhibitor at the ASM-Microbe 2024 Conference in Atlanta, GA
June 13-17
Exhibitor at the ARVO 2024 Vision for the Future Conference in Seattle, WA
May 5-9
Genesis Drug Discovery & Development Attends Society of Toxicology Annual Meeting in Salt Lake City
Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.
Genesis Biotechnology Group announces second year of CRO relationship with Yale University
Genesis Drug Discovery & Development Appoints Anthony Rohr as Chief Operating Officer
Genesis Biotechnology Group Appoints Erich E. Dagnal as Director of Mergers & Acquisitions
Genesis Biotechnology Group® (GBG) Announces First Annual Community Fall Fest in Hamilton
Genesis Drug Discovery & Development Announces Operating Agreement with Ophthy-DS, Inc.
Genesis Biotechnology Group announces partnership with Yale University
Genesis Biotechnology Group® Acquires Assets of 4path, Ltd to Expand their Diagnostic Branch
Genesis Biotechnology Group Expands Preclinical Contract Research Portfolio by Acquiring PharmOptima
Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Test
Mercer Regional Chamber of Commerce 2011 Award
Announcing new testing for Aerobic Vaginitis (AV)
A Complimentary Reflex Test to Determine Metronidazole Resistance in Trichomonas vaginalis.